Publications by Harald Bull Ragnum
11 publications found
Original articles
Prostate cancer radiogenomics reveals proliferative gene expression programs associated with distinct MRI-based hypoxia levels
Radiother Oncol, 188, 109875
DOI 10.1016/j.radonc.2023.109875, PubMed 37640161
A prognostic hypoxia gene signature with low heterogeneity within the dominant tumour lesion in prostate cancer patients
Br J Cancer, 127 (2), 321-328
DOI 10.1038/s41416-022-01782-x, PubMed 35332267
Comparison of time curves from dynamic 18F-fluciclovine positron emission tomography and dynamic contrast-enhanced magnetic resonance imaging for primary prostate carcinomas
Phys Imaging Radiat Oncol, 7, 51-57
DOI 10.1016/j.phro.2018.09.003, PubMed 33458405
Combined MR Imaging of Oxygen Consumption and Supply Reveals Tumor Hypoxia and Aggressiveness in Prostate Cancer Patients
Cancer Res, 78 (16), 4774-4785
DOI 10.1158/0008-5472.CAN-17-3806, PubMed 29945958
Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition
Br J Cancer, 115 (8), 929-939
DOI 10.1038/bjc.2016.278, PubMed 27599042
The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer
Br J Cancer, 112 (2), 382-90
DOI 10.1038/bjc.2014.604, PubMed 25461803
Hypoxia-independent downregulation of hypoxia-inducible factor 1 targets by androgen deprivation therapy in prostate cancer
Int J Radiat Oncol Biol Phys, 87 (4), 753-60
DOI 10.1016/j.ijrobp.2013.07.023, PubMed 24035332
Hypoxic tumor kinase signaling mediated by STAT5A in development of castration-resistant prostate cancer
PLoS One, 8 (5), e63723
DOI 10.1371/journal.pone.0063723, PubMed 23675504
[A man in his 50's with hypotension and hyponatremia]
Tidsskr Nor Laegeforen, 131 (20), 2009-11
DOI 10.4045/tidsskr.10.0021, PubMed 22016128
Other articles
A man in his sixties with dyspnoea following immunotherapy
Tidsskr. Nor. Laegeforen., 141 (12), 1190-1194
A man in his sixties with dyspnoea following immunotherapy
Tidsskr Nor Laegeforen, 141 (2021-12)
DOI 10.4045/tidsskr.21.0139, PubMed 34505469